Listen to this article
All participants in the prescription drug supply chain deserve scrutiny, but weakening the mechanisms that extract price concessions will not lower drug spending. The more likely outcomes are gains for drug companies and less efficient pharmacies, and higher drug costs. Effects will be especially felt by seniors on Medicare and by smaller employers that lack the leverage to offset the law’s new constraints.
，推荐阅读谷歌浏览器下载获取更多信息
Therefore I’ve left Valais out of the scope of this post: better no data than incorrect data.
同日，中國商務部發布2026年第11號及第12號公告，將20家日本實體列入「出口管制清單」，禁止任何兩用物項出口給其軍事用途；另20家列入「關注清單」，要求嚴格審查最終用戶與用途。
“한국 교회 큰 위기…설교 강단서 복음의 본질 회복해야”